Form 4: Immuneering CPO Granted 140,000 Stock Options

Immuneering Corp's Chief People Officer, Leah R. Neufeld, was granted 140,000 stock options with an exercise price of $4.91, vesting over four years.

Summary

• Leah R. Neufeld, Chief People Officer of Immuneering Corp (IMRX), was granted 140,000 stock options.
• The options have an exercise price of $4.91 per share.
• The transaction date for the option grant was February 3, 2026.
• The options vest in equal monthly installments over a four-year period, commencing on February 1, 2026.
• The options will be fully vested and exercisable on January 1, 2030.
• The expiration date for these stock options is February 3, 2036.
• Following this transaction, Leah R. Neufeld beneficially owns 140,000 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive alignment with shareholder interests through equity compensation, which is a standard and healthy practice for public companies.

Positives

• The grant of stock options to the Chief People Officer aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The vesting schedule over four years promotes long-term commitment from a key executive.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on an insider's stock option grant.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the Chief People Officer is a standard practice in the biotechnology and pharmaceutical industries. This compensation structure is designed to attract, retain, and motivate talent by linking their personal financial success to the company's long-term share price performance. It is a common mechanism for aligning executive incentives with shareholder value creation.

Comparison to Industry Standards

• StockSavvy.ai observes that the grant of 140,000 stock options to a Chief People Officer is within the typical range for executive compensation packages at similar-sized biotech companies, such as those with market capitalizations comparable to Immuneering Corp. For instance, companies like Relay Therapeutics (RLAY) or Black Diamond Therapeutics (BDTX) often utilize similar equity-based incentives for their senior leadership to foster long-term commitment and performance.
• The four-year monthly vesting schedule is a common industry standard, providing a balance between immediate incentive and long-term retention, comparable to vesting schedules seen at companies like Arvinas (ARVN) or Kymera Therapeutics (KYMR).

Stakeholder Impact

• Shareholders: The option grant aligns the Chief People Officer's financial incentives with the company's long-term stock performance, potentially benefiting shareholders through improved executive motivation and retention.
• Employees: The Chief People Officer's role is critical for human capital strategy, and this grant may signal stability and confidence in the company's leadership, indirectly benefiting employees.

Next Steps

• The stock options will continue to vest in equal monthly installments over the next four years, commencing February 1, 2026.
• The options will become fully exercisable on January 1, 2030.

Key Dates

Keywords

Immuneering Corp, IMRX, Stock Options, Executive Compensation, Insider Transaction, Form 4, Leah R. Neufeld, Chief People Officer